Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Stool test could replace endoscopy for h. pylori treatment decisions

NCT ID NCT05495854

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times

Summary

This study tested whether a simple stool test can guide doctors in choosing the right antibiotics for H. pylori infections, avoiding the need for an invasive stomach camera procedure. The test detects the bacteria and checks for antibiotic resistance, aiming to improve cure rates. The study involved 246 adults in primary care and measured success with a breath test six weeks after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

245 people

The number who actually took part.

Started

Feb 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Person over 18 years old * Patient affiliated or beneficiary of a social security scheme. * Informed consent signed by the patient after clear and fair information about the study * Patient registered on the list of patients who signed a doctor's statement with the investigating doctor. * Patient with an indication for research and treatment of an Hp infection according to National Health Authority (HAS) recommendations: 1. Suffering from (at least one) : Chronic dyspepsia; Iron deficiency anemia without a found cause or resistant to iron supplementation; Vitamin B12 deficiency without a found cause; familial gastric cancer DCDS; Immunological thrombocytopenic purpura in adulthood; history of peptic ulcers or precancerous lesions that have not been eradicated; Long-term consumption of NSAIDs; Long-term PPI consumption. or 2. Patient who received Hp eradication treatment without eradication control. or 3. Patient with risk factors for gastric cancer: person related to a patient who has had stomach cancer (parents, brothers / sisters, children). or 4. Patient with a syndrome of predisposition to digestive cancers (Hereditary non-polyposis colorectal carcinoma cancer HNPCC / Lynch syndrome). or 5. Patient who has had a partial gastrectomy or endoscopic treatment of gastric cancerous lesions. or 6. Patient with pre-neoplastic gastric lesions (severe atrophy and / or intestinal metaplasia, dysplasia). or 7. Patient who has already undergone an endoscopy with detection of Hp but without antibiotic sensitivity test (biopsy not addressed in bacteriology) and for whom we want to undergo a guided treatment. Exclusion Criteria: * Patient benefiting from enhanced protection, namely minors, pregnant or breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social establishment, adults under legal protection and finally patients in emergency situations. * Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception (hormonal / mechanical: oral, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy). Exclusion criteria related to non-compliance with ambivalence: * Allergy to amoxicillin (suspected or documented). * Contraindication to eso-gastro-duodenal fibroscopy and biopsies. * Use of antibiotic within 15 days before enrolment. * Patient with an indication to perform an endoscopy of the upper digestive system in Emergency according to the criteria of "the European Panel on the Appropriateness of Gastrointestinal Endoscopy (EPAGE II)": upper gastrointestinal hemorrhage; acute deglobulization without digestive hemorrhage externalized; ingestion of caustics; acute dysphagia or ingestion of foreign bodies. * Participating another interventional trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Helicobacter pylori infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ANDRIEUX Marine

    Vaux-sur-Mer, France

  • ARCHAMBAULT Pierrick

    Nueil-les-Aubiers, France

  • Christophe BONNET

    Tonnay-Charente, France

  • Claude SAPIN

    La Roche-Posay, France

  • Elodie POUPIN

    Saint-Germain-de-Marencennes, France

  • FRECHE Bernard

    Vaux-sur-Mer, France

  • Gwenaelle FARCY

    La Mothe-Saint-Héray, France

  • Lise BLANCHARD

    Mignaloux-Beauvoir, France

  • Marc CHABANNE

    Pont Labbe Darnoult, France

  • Marie ROCHEPEAU

    La Mothe-Saint-Héray, France

  • Vincent HELIS

    Frontenay-Rohan-Rohan, France

  • Vincent JEDAT

    Saint-Jean-d'Angély, France

  • philippe BRAVIN

    Jarnac-Champagne, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.